Resource Center - Cholesterol Lowering

Managing Obesity: Tips on Prevention and Treatment

Topic-Based
Resource Centers

Lipid-Lowering Potential in the Immunocompromised

Stay up-to-date with the latest studies in statins, cholesterol treatment and medications. Assess the risks and benefits in deciding on statin use.
TAGS Statins HIV Cholesterol Cardiology Heart Disease Clinical Study Rx Care

RELATED ARTICLES


	FDA approves orphan drug for inherited cholesterol disorder FDA approved mipomersen sodium (Kynamro, Genzyme and Isis Pharmaceuticals) once-a-week injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). More...

	Social value of statins merits actions to broaden treatment, improve adherence, study finds New evidence suggests that statins generate large survival and health benefits at the population level and greater use of and adherence to statins should be encouraged, according to a study published in the October issue of Health Affairs. More...

	Statin use may be linked to increase in cataract risk A recent study indicates that patients taking statins are at a higher risk of developing cataracts at an earlier age than those not taking them. More...

	An emerging dyslipidemia: Assessing future CV risk in children New research on the natural history of familial hypercholesterolemia, a genetic disorder present in 1/500 of the general population, has demonstrated the adverse effects of chronic long-term exposure to elevated low-density lipoprotein (LDL) cholesterol and has prompted new recommendations regarding its management More...

CME

Clinical Utility of Non-HDL-Cholesterol in the Management of Dyslipidemia

Release Date: March 14, 2012
Expiration Date: March 14, 2013

Learning Objectives:

Identify the clinical significance of non-HDL-C compared to LDL-C

Determine the non-HDL-C goals according to the most recent NCEP ATP III update

Describe the mechanisms by which different classes of drugs affect non-HDL-C

Explain the components of non-HDL and identify the techniques to measure non-HDL as well as Apo B and LDL-P

TOOLS

Statin Dose Limitations

Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase risk of muscle injury

In March 2012 the FDA issued recommendations concerning interactions between drugs for HIV or hepatitis C virus. Labeling for both the HIV protease inhibitors and certain statins have been updated to contain interaction information and dosing recommendations for those statins that may safely be co-administered with HIV or HCV protease inhibitors.

Lipid-Lowering Potential in the Immunocompromised

Clinical

Business

HOT TOPICS

	Home \| About us \| Contact us \| Advertise \| All Content \| Editorial and Advertising Policy \| Terms and Conditions \| Privacy Policy \| Terms of Use \| Advertiser Terms \| Linking and RSS policy
	© 2013 Advanstar Communications, Inc. All rights reserved. Reproduction in whole or in part is prohibited. Please send any technical comments or questions to our webmaster.